https://www.nih.gov/news-events/nih-research-matters/long-covid-symptoms-linked-inflammation?fbclid=IwAR3TSxW5puKjkbBmY2mKCVZSas8Jr-_4o2FpKz4m-JuJXVXT8bKruGpIi0o

btw, stopping p2 covid therapeutics trials early has been a trend recently for several reasons:

1) as pandemic becomes endemic, less financial incentive

2) juridictions start to discontinue emergency authorization soley based on p2 data

3) obviously the problem with recruitment..

this stopping early has happened to many other pharma companies too